Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
Diabetes Metab Syndr Obes. 2013 Apr 8;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
Qsymia™（Vivus Inc，美国加利福尼亚州山景城），一种包含苯丁胺和缓释托吡酯的复方制剂，自 2012 年 9 月起在美国获准用于肥胖症的治疗。苯丁胺是一种厌食药，被批准用于短期肥胖治疗，而托吡酯则被批准用于非减肥适应症——癫痫发作和偏头痛预防。与单一药物治疗相比，联合治疗的减重效果更为显著。联合治疗中出现的不良反应与组成药物的已知副作用特征一致；致畸性、心率略有增加、精神和认知不良反应以及代谢性酸中毒是需要关注的问题。
